Type 1 diabetes is a chronic autoimmune disease in which the immune system destroys insulin-producing beta cells, resulting in absolute insulin deficiency and lifelong insulin replacement needs.
Biotech funding roundup: $8M CIRM grant to Siren, $3.5M pre-seed for Claryx, Syntax Bio's $14.4M Series A, €80M Novo Nordisk Foundation programme, and Appili's NIAID contract termination.
A prototype smart ring tracks multiple metabolic biomarkers in sweat, while Amazon One Medical launches Health Insights for blood biomarker analysis. Pharmacies are also using point-of-care testing to personalize supplement recommendations.
Engineered extracellular vesicles deliver IL-2 and therapeutic antibodies with precision, reducing systemic toxicity and targeting inflamed tissues in autoimmune disease, cancer, and inflammatory bowel disease. Microfluidic electroporation enables efficient IL-2 loading, while exosome nanovesicles show efficacy in preclinical colitis models.
The FDA approved Tzield for stage 3 type 1 diabetes, and the therapy was given to children in Canada for the first time. Research also advanced on engineered islets and stem-cell treatments.
Crispr Therapeutics AG trades at $47.78 with a $4.78B market cap, while Moderna trades at $61.82 with a $25.06B market cap, about 5.2 times larger. Both face losses, but CRISPR's Casgevy approval and Moderna's pipeline advances shape divergent analyst outlooks.
Vertex Pharmaceuticals dominates cystic fibrosis therapies with TRIKAFTA/KAFTRIO generating $2.57 billion in Q4 2025 and ALYFTREK ramping to $380.1 million. The company posted strong free cash flow of $3.19 billion in 2025 and is expanding into pain, kidney disease, and gene-editing therapies.
Atezolizumab plus capecitabine showed no significant survival benefit in residual TNBC. Other reports covered HER2-low AR enrichment, first-line ADC choices, and a self-management planner.
A living insulin implant from Technion researchers achieved one year of steady blood sugar control in diabetic mice, while millions worldwide still lack access to insulin medication. Animal trials showed beta cells could auto-dose insulin, though immune barriers remain before human trials. Meanwhile, only about half of type 2 diabetes patients globally have access to needed insulin, with the problem affecting both low- and high-income countries.
Research has identified CD27 expression as a potential biomarker for monitoring regulatory T cell (Treg) induction efficacy in clinical trials. Studies show CD27 marks memory-like Tregs with superior suppressive capacity, correlating with immune regulation in type 1 diabetes patients. Treg-based tolerance restoration is emerging as a therapeutic strategy for autoimmune diseases and transplantation.
Sequel Med Tech reported positive pivotal trial results for its twiist Automated Insulin Delivery System in adults with type 2 diabetes. The 13-week study showed meaningful improvements in HbA1c and time in range with no severe hypoglycemia events. Separately, Sequel and Senseonics launched the twiist system integrated with Eversense 365 CGM across the U.S.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07774780 |
Oral Galactose as a Substrate for Post-Exercise Skeletal Muscle Glycogen Repletion in Individuals With Type 1 Diabetes |
NOT_YET_RECRUITING | NA |
| NCT07769138 |
Implementation of Networked Continuous Glucose Monitoring With Telemetry Within the Intensive Care Unit (ICU-TeleCGM) |
NOT_YET_RECRUITING | |
| NCT07750210 |
Study of Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) in Adults With Type 1 Diabetes |
NOT_YET_RECRUITING | |
| NCT07739342 |
Evaluating the Occurrence of DKA in People With Type I Diabetes |
NOT_YET_RECRUITING | |
| NCT07706803 |
Screening For Social Determinants Of Health In Routine Diabetes Care |
NOT_YET_RECRUITING | NA |
| NCT07696780 |
Diabetes Management Among Women Using an AID System: a Mixed Method Study |
COMPLETED | |
| NCT07695727 |
Targeting GLUT1 to Control Autoimmunity in Type 1 Diabetes |
NOT_YET_RECRUITING | |
| NCT07689318 |
Effect of a Structured Educational Intervention Through Mobile App on Hemoglobin A1c (HbA1c), Self-Efficacy and Self- Care in Adolescent With Type 1 Diabetes (T1DM) |
NOT_YET_RECRUITING | NA |
| NCT07684248 |
Butyrate or Intensive Lifestyle Modification in Type 1 Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease |
NOT_YET_RECRUITING | NA |
| NCT07680673 |
ENCRT-103-hPI: Evaluation of an Immune-protected ENCRT-103-hPI Containing Primary Human Islets in Adults With Type 1 Diabetes, With and Without Standard-of-care Portal Vein Islet Infusion. |
NOT_YET_RECRUITING | PHASE1 |
